Literature DB >> 19794436

Santhera licenses novel dyskinesia therapy to Biovail.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19794436     DOI： 10.1038/nrd3009

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

Review 1.  Novel pharmacological targets for the treatment of Parkinson's disease.

Authors:  Anthony H V Schapira; Erwan Bezard; Jonathan Brotchie; Frédéric Calon; Graham L Collingridge; Borris Ferger; Bastian Hengerer; Etienne Hirsch; Peter Jenner; Nicolas Le Novère; José A Obeso; Michael A Schwarzschild; Umberto Spampinato; Giora Davidai
Journal:  Nat Rev Drug Discov       Date:  2006-10       Impact factor: 84.694
  1 in total
  1 in total

1.  Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.

Authors:  Christopher J Barnum; Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Stefanie Tignor; Anna Klioueva; Hannah Walters; Christopher Bishop
Journal:  Pharmacol Biochem Behav       Date:  2011-09-25       Impact factor: 3.533
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.